Her2-receptor negative breast cancer

This study tested whether adding the drug nintedanib to standard chemotherapy (docetaxel) helps people with advanced HER2-negative breast cancer live longer without their disease getting worse. Fifty-one adults who had already received some treatment took part. The goal was to se…

This trial tests three different schedules of the chemotherapy drug nab-paclitaxel (Abraxane) in women with HER2-negative metastatic breast cancer. The goal is to find a schedule that allows patients to stay on treatment longer, potentially improving progression-free survival, wh…

This phase II trial tested the drug alisertib, alone or combined with fulvestrant, in 96 postmenopausal women with advanced breast cancer that no longer responds to hormone therapy. Alisertib blocks enzymes that help cancer cells grow, while fulvestrant blocks estrogen. The goal …

This study tests whether giving 6 months of hormone therapy before surgery helps remove all cancer cells in women with early-stage, estrogen-positive breast cancer. It involves 8 postmenopausal women with low-risk, node-negative tumors. The goal is to see if this approach leads t…

This trial is testing whether adding an experimental drug called BYL719 to standard hormone therapy (letrozole) can better fight hormone receptor-positive metastatic breast cancer in post-menopausal women. BYL719 targets a protein that helps cancer cells grow, while letrozole blo…

This phase III trial is testing whether a combination of docetaxel and cyclophosphamide works as well as or better than anthracycline-based chemotherapy (like doxorubicin) for women with HER2-negative breast cancer that has spread to lymph nodes or is high-risk. The study aims to…

This trial compares two chemotherapy drugs—cabazitaxel given every three weeks versus paclitaxel given weekly—as a first treatment for HER2-negative metastatic breast cancer. About 90 to 160 participants receive 18 weeks of one of the two drugs. The main goal is to see which drug…

This pilot study tests whether adding a special heat therapy (multimodal thermal therapy) to standard chemotherapy and immunotherapy can help the immune system better recognize and attack HER2-negative breast cancer. The study enrolls women aged 18–70 with certain subtypes of bre…

This phase II trial studied 92 women with early-stage breast cancer to see how well chemotherapy (paclitaxel and cyclophosphamide) with or without trastuzumab works before surgery. The main goals were to check side effects and see if the tumor disappears completely by the time of…

This large phase III trial tests which of three chemotherapy drugs—paclitaxel, nab-paclitaxel, or ixabepilone—works best, with or without the targeted drug bevacizumab, for people with stage IIIC or IV breast cancer that has returned or spread. The study aims to find the most eff…

This phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy carboplatin could help people with HER2-negative metastatic breast cancer that has spread. The 12 participants had cancer cells in their blood and had already tried …

This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…

This study tested a new chemotherapy drug called WH002 against the standard drug paclitaxel in 40 women with HER2-negative breast cancer. Both drugs were given before surgery, followed by two other chemotherapy drugs. The main goal was to compare side effects and how well the tum…

This early-phase study tested a new drug called ONO-4578 combined with standard hormone therapy and targeted drugs (letrozole plus palbociclib or abemaciclib) in 46 postmenopausal women with advanced or recurrent hormone receptor-positive, HER2-negative breast cancer. The main go…

This study tested a new oral drug called OP-1250 in 153 adults with advanced or metastatic hormone-receptor-positive, HER2-negative breast cancer. The drug works by blocking estrogen receptors more completely than current therapies. The trial aimed to find the best dose, check sa…

This study looked at how well older adults (70+) with advanced, hormone-sensitive breast cancer tolerate a combination of palbociclib and either letrozole or fulvestrant. The goal was to see if the treatment is safe and effective in this age group. 93 participants were enrolled, …

This study tested leflunomide, a pill usually used for arthritis, in 17 women with metastatic triple negative breast cancer (a fast-growing type). The goal was to see if it is safe and can help control the cancer. The drug works by blocking a protein the cancer needs to grow.

This study looked at whether a test called RAD51-foci can predict how well the drug olaparib works in people with advanced HER2-negative breast cancer who have certain gene mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D). About 65 participants received olaparib, and researcher…

This early-phase trial tested a new drug called ALRN-6924 combined with the chemotherapy paclitaxel in 28 adults with advanced solid tumors that had spread or couldn't be removed by surgery, including a type of breast cancer. The main goal was to find the safest dose and check fo…

This early-phase study tested two drugs, abemaciclib and niraparib, given together before surgery in 8 people with hormone receptor-positive, HER2-negative breast cancer. The goal was to find the best dose and see if the combination could shrink tumors safely. The study focused o…

This early-phase trial tested a new oral drug called ART4215 in 93 people with advanced or metastatic solid tumors, including breast cancer. The main goals were to find a safe dose and check for side effects when given alone or with other cancer drugs (talazoparib or niraparib). …

This study tested a combination of two drugs, palbociclib and tamoxifen, as the first treatment for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). The goal was to see how long the cancer could be kept from growing. 49 participants took both pil…

This phase II trial tested a combination of hormone therapy drugs (fulvestrant or an aromatase inhibitor) plus palbociclib in 14 elderly patients with hormone-responsive breast cancer who either had inoperable tumors or were too frail for surgery. The goal was to see if this drug…

This study looked at 155 people with metastatic breast cancer whose original tumors were HER2-negative. Researchers checked their blood for HER2-positive cancer cells. Those who had them received the drug T-DM1, which delivers chemotherapy directly to HER2-positive cells. The goa…

This study looked at whether adding a drug that targets specific genetic changes in breast tumors could slow cancer growth more than standard hormone therapy alone. It involved 19 people with ER-positive, HER2-negative breast cancer who received treatment before surgery. The goal…

This study looked at whether a blood test called DiviTum-TKa can help doctors check if patients with metastatic breast cancer are taking their CDK4/6 inhibitor medication correctly and if other drugs are interfering. The test measures a marker of cell growth to see if the treatme…

This completed study analyzed data from 1,415 patients with HR-positive, HER2-negative metastatic breast cancer in the United States. Researchers looked at what happened after patients progressed on their first-line treatment (endocrine therapy plus a CDK4/6 inhibitor) and starte…

This study reviewed medical records of over 1,100 people with a type of breast cancer called HER2-negative that had spread and stopped responding to treatment. Researchers wanted to find out how many of these patients actually have a subtype called HER2-low, and to understand the…

This study reviewed medical records of 405 people in Egypt with advanced HER2-negative breast cancer to find out how many actually have a subtype called HER2-low. Researchers looked at past test results to estimate the prevalence. The goal is to better understand who might be eli…